Using GLP-1s During Menopause: What Women Need to Know

Woman fanning herself with an orange hand fan — Photo: fizkes / Shutterstock

Women going through menopause lose just as much weight on GLP-1 drugs as younger women, but doctors say the number on the scale is not the whole story.

Quick Take

Studies show GLP-1 drugs like tirzepatide and semaglutide work well for weight loss in postmenopausal women.
A Mayo Clinic study found women on hormone therapy lost 35% more weight while taking tirzepatide.
Falling estrogen levels shift fat to the belly and can shrink lean muscle, changing what “weight loss” really means.
Researchers now urge doctors to track bone density, muscle mass, and blood markers, not just pounds lost.

Menopause Does Not Block GLP-1 Results

New research puts to rest any worry that menopause blunts these drugs. A 2025 post-hoc analysis from NewYork-Presbyterian and Weill Cornell Medicine found tirzepatide cut body weight, waist size, and waist-to-height ratio no matter what reproductive stage a woman was in. A separate review of daily oral GLP-1 medication found similar results, with women losing up to 14% of their body weight across all three menopause stages.

That is good news for the millions of women who hit midlife and watch stubborn fat settle around their midsection. Falling estrogen pushes fat storage toward the belly and away from the hips, a shift tied to higher risk for heart disease and diabetes. Drugs that shrink waist circumference, not just overall weight, are hitting the part of the problem that matters most for long-term health.

Hormone Therapy Changes The Math

Here is where things get interesting. A Mayo Clinic study found postmenopausal women on menopausal hormone therapy lost 35% more weight while taking tirzepatide compared to women taking the drug alone. Research published in the journal Menopause backed this up, showing hormone therapy users saw greater weight loss with semaglutide than those not on it. Reduced estrogen appears to blunt how well these drugs work on their own.

That does not mean every woman needs hormone therapy to benefit. It does mean doctors treating midlife weight gain now have two tools that seem to work better together than either one alone. A clinical trial is currently testing combined hormone therapy and GLP-1 treatment specifically in postmenopausal women with diabetes, aiming to nail down how much the combination improves blood sugar control.

The Scale Does Not Tell The Whole Story

Losing weight is not the same as losing only fat. Studies show that of all the weight people lose on GLP-1 drugs, roughly one quarter to nearly half can be lean muscle mass, not fat. For women already losing muscle and bone density due to menopause, that trade-off deserves real attention. One Colorado research team is now tracking women for a full year after weight loss to see how much lean mass and bone density they regain or keep losing.

Bone health has become a central worry. Some researchers call menopause plus GLP-1 use a “perfect storm” for bone loss, since both estrogen decline and rapid weight loss can weaken bones on their own. Other reviews say the evidence on bone outcomes is genuinely mixed, with some GLP-1 drugs linked to lower fracture risk and others showing no benefit at all. Major clinical trials so far have not found an increased fracture risk, but doctors say weight loss itself, regardless of the cause, can still stress the skeleton.

What Doctors Now Recommend Tracking

Physicians who specialize in menopause care say the answer is not to avoid these drugs, but to widen what gets measured. One doctor recommends checking fasting insulin, hemoglobin A1C, a full lipid profile, and inflammation markers like C-reactive protein before and during treatment. Belgium’s menopause society has echoed this, noting GLP-1 drugs work especially well in postmenopausal women on hormone therapy but still call for careful monitoring of overall health, not just weight.

Postmenopausal women on tirzepatide lost more weight if they were also on menopause hormone therapy. Most people do not expect that.

A Mayo Clinic retrospective cohort in The Lancet Obstetrics, Gynaecology, & Women’s Health looked at 120 postmenopausal women with overweight or…

— Dr. K, M.D. (@DrKERMD) September 22, 2026

The bigger picture here is straightforward. GLP-1 drugs are proving to be powerful, effective tools for women well past their reproductive years, and pairing them with hormone therapy can boost results even further. But smart use means watching bone scans, blood work, and muscle mass alongside the number on the scale. For women and their doctors navigating this new territory, that broader view is quickly becoming the standard of care rather than the exception.